<DOC>
	<DOCNO>NCT00604786</DOCNO>
	<brief_summary>This research do study effect drug omalizumab ( Xolair ) people cat allergy . The investigator use omalizumab study change cell nose , skin blood cause allergy . The investigator predict cell blood effect cell nose skin .</brief_summary>
	<brief_title>The Effect Omalizumab Responses Cat Allergen Challenge</brief_title>
	<detailed_description>Omalizumab monoclonal antibody direct Immunoglobulin E ( IgE ) FDA-approved use allergic asthma , though clinical role precisely define . It bind IgE site Fc domain high affinity IgE receptor ( FcεRI ) , therefore , block interaction IgE mast cell basophils . It , therefore , may use mechanistic tool study IgE . As IgE level reduce omalizumab , FcεRI expression human basophils reduce . This reduction basophil receptor allergen induced activation pronounce within 7 day initial administration reversible omalizumab administration discontinue . The omalizumab-induced reduction mast cell FcεRI expression function unchanged day 7 significantly reduce day 70 . These change base upon intravenously administer omalizumab dose 0.03 mg/kg/IU IgE/mL total three subject . We propose exploit kinetics faster omalizumab effect circulate basophil relative tissue mast cell elucidate role basophil versus mast cell activation nasal airway allergen challenge , study date .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Ability understand provide inform consent Male Female ( nonpregnant ) , age 1850 Females must : Surgically sterile ( hysterectomy , bilateral oophorectomy , bilateral tubal ligation ) , OR postmenopausal ( least 1 year since last menses ) , OR use medically acceptable form birth control throughout duration study . Clinical history seasonal perennial allergic rhinitis least two year , without mild persistent asthma Positive puncture skin test great equal 5 mm diluent control Positive Immunocap Fel 1 &gt; 0.35 kallikrein unit/L Positive intranasal cat allergen challenge define &gt; 5 sneeze triple measure nasal lavage mediator In vitro assay basophil responsiveness cat allergen great 20 % histamine release The use antihistamine , cromolyn , leukotriene modifier nonsteroid ( astelin topical decongestant ) , nasal medication allow , withhold 5 day prior nasal allergen provocation session . Inhaled corticosteroid mild asthma permissible . No known contraindication therapy omalizumab Asthma force expiratory volume one second ( FEV1 ) &lt; 80 % , moderate severe asthma classification per National Asthma Education Prevention Program Expert Panel ( NAEP ) Standards ( 1997 National Asthma Education Prevention Program Expert Panel Report II guideline ) Serum IgE level less 30 IU/mL great 700 IU/mL time enrollment exclude Unexplained elevation erythrocyte sedimentation rate ( ESR ) , hematocrit &lt; 32 % , white blood cell ( WBC ) count 2400/microliter low limit normal , platelet &lt; 75000/microliter , creatinine &gt; 141.4 micromolar/L , aspartate aminotransferase ( AST ) &gt; 100 IU/L Body weight less 30 kg great 150 kg exclude . Plans become pregnant breastfeed exclude study A perforate nasal septum , structural nasal defect , large nasal polyp cause obstruction , evidence acute chronic sinusitis A life expectancy le 6 month A terminal illness determine investigator A history malignancy , anaphylaxis bleeding disorder also exclusion illness . Mental illness history drug alcohol abuse , opinion investigator , would interfere participant 's ability comply study requirement . Inability unwillingness participant give write informed consent comply study protocol Use investigational drug within 8 week participation Contraindications omalizumab include patient previous hypersensitivity omalizumab Recent recipient license investigational live attenuate vaccine ( ) within two month study initiation flu mist . Prior use omalizumab Frequent sinusitis ( &gt; 2/ documented episode per year ) active sinusitis within 2 week enrollment Use immunotherapy within last 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Basophils</keyword>
	<keyword>Mast Cells</keyword>
	<keyword>IgE</keyword>
	<keyword>IgE receptor</keyword>
	<keyword>omalizumab</keyword>
</DOC>